A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy

Overview

REaCT-5G will compare bone pain from a single dose of Pegfilgrastim to 5 doses of daily filgrastim in breast cancer patients receiving neoadjuvant/adjuvant chemotherapy.

Full Title of Study: “A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy (REaCT-5G)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 2023

Detailed Description

The use of granulocyte colony-stimulating factors (G-CSF) significantly reduces febrile neutropenia (FN) risk and has helped maintain dose intensity and dose density when treating breast cancer with chemotherapy. This is crucial as survival outcomes are significantly impaired if dose intensity are reduced. National and international guidelines recommend the use of G-CSF as primary prophylaxis with most commonly used breast cancer chemotherapy regimens. Filgrastim (FIL) as a G-CSF that has been in use since the early 90s. Pegfilgrastim (PEG) is a long-acting, pegylated version of FIL that requires only one injection per chemotherapy cycle instead of daily FIL injections for 5 to 10 days per cycle. PEG and FIL both come at the potential cost of bone pain, the most common side effect. G-CSF related bone pain is often severe, leading to refusal or cancellation of G-CSF and early discontinuation of chemotherapy. We propose to perform a pragmatic, multicenter, open-label, randomized clinical trial to compare bone pain experienced by patients receiving either PEG or 5-day-FIL with neoadjuvant or adjuvant chemotherapy.

Interventions

  • Drug: Filgrastim
    • Receive filgrastim subcutaneous injection once daily for five consecutive days starting 24-72 hours after chemotherapy
  • Drug: Pegfilgrastim
    • Receive pegfilgrastim as a single dose subcutaneous injection 24-72 hours after chemotherapy

Arms, Groups and Cohorts

  • Active Comparator: 5 Days of Filgrastim
    • Receive filgrastim subcutaneous injection once daily for five consecutive days starting 24-72 hours after chemotherapy.
  • Active Comparator: Pegfilgrastim
    • Receive pegfilgrastim as a single dose subcutaneous injection 24-72 hours after chemotherapy

Clinical Trial Outcome Measures

Primary Measures

  • Bone pain
    • Time Frame: 5 days after first G-CSF injection
    • Bone pain over the first 5 days after the administration of G-CSF. The total measure of bone pain over the five days will be summarized by the area under the curve (AUC) based on a patient’s daily pain score, starting after the first dose of G-CSF injection.

Secondary Measures

  • Incidence of Febrile Neutropenia
    • Time Frame: 2.5 years after study initiation
    • Number of times participants have Febrile neutropenia during chemotherapy treatment
  • Incidence of treatment-related hospitalizations
    • Time Frame: 2.5 years after study initiation
    • Number of times participants have a treatment-related hospitalization
  • Incidence of chemotherapy alteration
    • Time Frame: 2.5 years after study initiation
    • Number of times participants have a chemotherapy alteration including: dose delay, reduction and/or discontinuation
  • Incidence of chemotherapy-related mortality
    • Time Frame: 2.5 years after study initiation
    • Number of times there is a chemotherapy-related mortality
  • Rate of G-CSF compliance as prescribed
    • Time Frame: 2.5 years after study initiation
    • Number of times there is a G-CSF compliance
  • Differences in healthcare resource utilization
    • Time Frame: 2.5 years after study initiation
    • Differences in healthcare resource utilization: number of emergency room visits, number of planned/unplanned provider clinic visits (including stretcher bay), patient-reported phone calls or email to patient support line or provider, and additional medication use or management strategies related to G-CSF side effects or efficacy
  • HR-QoL
    • Time Frame: 2.5 years after study initiation
    • HR-QoL based on EQ-5D-5L
  • Cost-effectiveness
    • Time Frame: 2.5 years after study initiation
    • Cost differences associated with prescribing Filgrastim and Pegfilgrastim
  • Patient G-CSF preference
    • Time Frame: 2.5 years after study initiation
    • To survey patient preference in selection of G-CSF treatment before and after undergoing chemotherapy and G-CSF treatment
  • Study feasibility
    • Time Frame: 1 year after study initiation
    • Interim analysis/feasibility. After the first year of study initiation, if study recruitment is less than 30% at one year (70 patients), or if there are unanticipated safety issues, a review of study conduct will be performed to consider stopping the study unless there are unexpected or exceptional reasons, or in the case of low recruitment, there is a plan to boost recruitment efforts

Participating in This Clinical Trial

Inclusion Criteria

  • Patients with early-stage or locally-advanced breast cancer receiving neoadjuvant or adjuvant chemotherapy requiring primary febrile neutropenia prophylaxis with G-CSF – Able to provide verbal consent – Able to complete questionnaires in English or French Exclusion Criteria:

  • No access to pegfilgrastim or filgrastim prior to randomization – Metastatic cancer – Known hypersensitivity to filgrastim or pegfilgrastim or one of its components

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Ottawa Hospital Research Institute
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Terry Ng, MD, Principal Investigator, Ottawa Hospital Research Institute

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.